新開源(300109.SZ):擬與北京永泰設合資公司 可將其高端技術引入新開源醫檢所與LDT平台
格隆匯4月13日丨 新開源(300109.SZ)公佈,公司全資子公司上海新開源精準醫療有限公司(“上海新開源”)擬與北京永泰生物製品有限公司(“北京永泰”)雙方共同投資1000萬元人民幣在上海市設立合資公司(“合資公司”)。上海新開源認繳註冊資本為人民幣700萬元,持股比例為70%;北京永泰以技術出資的方式認繳註冊資本,持股比例為30%。
合資公司經營範圍暫定為技術服務、技術開發、技術諮詢、技術交流、技術轉讓,技術推廣;從事貨物和技術的進出口業務;計算機軟件的技術開發、技術服務;企業管理諮詢;商務代理代辦服務;健康管理諮詢服務;第一類醫療器械銷售;化工產品銷售(不含許可類化工產品);化粧品零售;在線數據處理與交易處理業務(生物信息數據分析)。
合資公司尚未設立,相關信息以最終工商行政管理部門核准登記備案為準。
根據公司對精準醫療板塊的戰略規劃,北京永泰是國內領先的細胞免疫治療生物醫藥公司,專注於T細胞免疫治療的研發和商業化,其核心在研產品 EAL®是中國首款獲准進入II期臨牀實驗的細胞免疫治療產品,而細胞與基因治療產業與腫瘤伴隨診斷密不可分,新開源精準醫療戰略佈局致力於以腫瘤伴隨診斷為核心,腫瘤伴隨診斷轉化優勢技術將會是公司未來發展的重點之一,成立合資公司可將北京永泰的高端技術引入新開源醫檢所與LDT平台,幫助開展細胞治療相關檢測,同時也使公司未來在相關領域擁有全面、完整、極具競爭力的技術佈局。合資公司的成立對公司精準醫療板塊的發展具有深遠的意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.